In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Concurrent use of this medicine with any of the following medications is general···【more】
Release date:2026-01-26Recommended:169
While certain medications should not be used together at all, in other cases, it···【more】
Release date:2026-01-26Recommended:146
While exerting the intended therapeutic effects, a medication may also induce ce···【more】
Release date:2026-01-26Recommended:138
In addition to the intended effects, medications may cause some adverse reaction···【more】
Release date:2026-01-26Recommended:150
Lorlatinib is an antineoplastic (anticancer) medication. It interferes with the ···【more】
Release date:2026-01-26Recommended:139
Lorlatinib is indicated for the treatment of patients with metastatic non-small ···【more】
Release date:2026-01-26Recommended:152
Lorlatinib is a targeted therapy indicated for the treatment of ALK-positive non···【more】
Release date:2026-01-26Recommended:172
Lorlatinib is a targeted therapy indicated for the treatment of specific ALK or ···【more】
Release date:2026-01-26Recommended:227
The common adverse reactions of Lorlatinib include metabolic abnormalities, cent···【more】
Release date:2026-01-26Recommended:155
The side effects of lorlatinib involve multiple systems, including the central n···【more】
Release date:2026-01-26Recommended:163
Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK)/c-ros oncogene···【more】
Release date:2026-01-23Recommended:165
Lorlatinib is a third-generation dual-target inhibitor of ALK/ROS1, primarily in···【more】
Release date:2026-01-23Recommended:140